MAPT and frontotemporal dementia: It removed Aβ, tau, and α-synuclein oligomers, restored synaptophysin levels, enhanced BDNF expression and neurogenesis, and improved cognitive and motor function in mouse models of AD, FTD, DLB, and PD.